Effectiveness of Monoclonal Antibody Therapy for Preventing COVID-19 Hospitalization and Mortality in a Statewide Population.
R I Med J (2013)
; 106(5): 42-48, 2023 Jun 01.
Article
en En
| MEDLINE
| ID: mdl-37195162
ABSTRACT
BACKGROUND:
Monoclonal antibody (MAB) treatments for COVID-19 received Emergency Use Authorization in the United States.METHODS:
We used surveillance data from Rhode Island to conduct a retrospective, statewide cohort study to estimate the effectiveness of MABs for preventing hospitalization and death during periods when Alpha and Delta variants were predominant.RESULTS:
From 1/17/2021-10/26/2021, 285 long-term congregate care (LTCC) residents and 3,113 non-congregate patients met our eligibility criteria and received MAB; they were matched to 285 and 6,226 controls, respectively. Among LTCC residents, 8.8% (25/285) of patients who received MAB were hospitalized or died compared to 25.3% (72/285) of those who did not receive MAB (adjusted difference=16.7%, 95% confidence interval CI=11.0-22.3%). Among non-congregate patients, 4.5% (140/3,113) of patients who received MAB were hospitalized or died compared to 11.8% (737/6,226) of those who did not receive MAB (adjusted difference=7.2%, 95% CI=6.0-8.4%).CONCLUSIONS:
Administration of MABs led to an absolute reduction in hospitalization or death during periods when Alpha and Delta variants were predominant.Palabras clave
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
COVID-19
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article